ViroGates is an international Medtech company headquartered in Denmark, north of Copenhagen, in the heart of Medicon Valley.
ViroGates was founded in 2001, based on an invention coming from Hvidovre Hospital, Denmark.
Inventor and co-founder Jesper Eugen-Olsen discovered the utility of the biomarker suPAR in HIV. More than 700 publications have followed, substantiating suPAR as one of the most promising biomarker tools for various areas of healthcare. ViroGates has developed a patented product line called suPARnostic® to make the suPAR test commercially available.
The suPAR biomarker predicts negative patient outcomes across diseases by measuring the immune system’s activation level. suPARnostic® is a reliable prognostic tool that enables healthcare professionals to make quick and informed patient triaging decisions at hospital emergency departments.
Implementing suPAR in clinical care saves critical resources and valuable time, and results in vastly reduced healthcare costs, more efficient triage, and better patient outcomes. At hospital emergency departments, suPAR delivers faster and safer patient discharges, reduces readmissions, avoids unnecessary admissions, and lowers hospital length of stay.
Seamlessly implemented by clinician and laboratory technicians, suPARnostic products fit existing workflows in hospitals, are approved for all the major clinical chemistry analyzers, and delivers results in less than 20 minutes.
How suPARnostic® works at the Emergency Department
A patient is admitted to the ED for observation
The patient’s blood sample is drawn
The patient’s suPAR level is measured at the central lab
(~20 minutes) and fits existing hospital workflow.
The physician gets the result and makes a triage decision
“The key challenge for the ER is to identify ill patients faster, make diagnoses faster, find the right specialist faster and initiate the right treatment faster.”
– MD, Chief Physician Inger Søndergaard, Herlev Hospital, Copenhagen
Our Vision and Mission
We envision a world where the suPAR biomarker makes a difference in health management, by providing information that will empower the clinicians to save lives, reduce healthcare cost and provide patients the treatment or lifestyle changes they need.
It is our mission to develop and market rapid and affordable tests detecting the suPAR biomarker in acute situations, where clinicians need help to prioritize treatment for patients.